3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
15
Leukemia, Myeloid, Chronic-Phase
6
Neoplasm Metastasis
4
Neoplasms
3
Philadelphia Chromosome
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Leukemia
2
Synovitis, Pigmented Villonodular
1
Sarcoma
1
Recurrence
1
Peritoneal Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Giant Cell Tumor of Tendon Sheath
1
Genital Neoplasms, Female
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Chordoma
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Blast Crisis
1
Appendiceal Neoplasms
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
fludarabine
19
Whole-Body Irradiation
18
Cyclophosphamide
17
fludarabine phosphate
16
ruxolitinib
15
Mycophenolic Acid
14
Specimen Handling
13
Tacrolimus
11
Azacitidine
11
Biopsy
10
Peripheral Blood Stem Cell Transplantation
9
Melphalan
9
Cytarabine
9
venetoclax
8
Sirolimus
8
Busulfan
8
Stem Cell Transplantation
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Daunorubicin
5
Cyclosporine
5
CPX-351
5
luspatercept
4
ivosidenib
4
itacitinib
4
fedratinib
4
decitabine and cedazuridine drug combination
4
Thiotepa
4
Liposomes
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
nilotinib
×
1 year
×
Clear all
NCT05456191
2026-05-27
ASC4START
Novartis
Phase 3
Active not recruiting
568 enrolled
11 charts
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled